期刊文献+

异基因造血干细胞移植治疗慢性淋巴细胞白血病的研究进展 被引量:2

原文传递
导出
摘要 大多数慢性淋巴细胞白血病(CLL)患者发病时年龄较大,因CLL呈惰性病程,临床上通常不将高强度治疗方案作为治疗CLL的一线应用,但少数患者的CLL恶性程度高,病情进展较快,必要时需考虑行异基因造血干细胞移植(allo—HSCT)。鉴于allo-HSCT的风险较高,故明确适应证和选择移植时机至关重要。本文就异基因造血干细胞移植治疗慢性淋巴细胞白血病的进展作如下综述。
作者 陈佳 吴德沛
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2012年第7期444-446,共3页 Chinese Journal of Organ Transplantation
基金 受“江苏省临床医学中心(ZX201102)”资助
  • 相关文献

参考文献24

  • 1Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood, 2005, 106(13) :4389-4396.
  • 2Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant, 2009,15 ( 1 Suppl) : S53 58.
  • 3Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program, 2009 : 602-609.
  • 4Dreger P, D hner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 2010, 116(14) :2438-2447.
  • 5Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia.. impact of rituximab on immunomodulation and survival. Exp Hematol, 2004, 32(1) :28 35.
  • 6Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant, 2006, 12 (10): 1056-1064.
  • 7Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol, 2003, 21(14):2747-2753.
  • 8Caballero D, Garc a-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (llq- and 17p-). Clin Cancer Res, 2005, 11(21) :7757-7763.
  • 9Delgado J, Pillai S, Benjamin R, et al. The effect of in vivo Tcell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant, 2008, 14 (11): 1288-1297.
  • 10Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneie transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood, 2006, 107(4) : 1724-1730.

同被引文献10

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部